

Metrics for plain language summaries (PLS)

Quick and easy ways Datavision can help you

POWERING
PATIENT VOICES

PLS metric

Datavision use

1

How many (# and %) of our publication plan outputs include a PLS?

- Abstracts
- Poster/slide presentations
- Publications

Plan Items	Name	Version	Current Plan	Comms	Due Date	Status	Type
Start		May 01, 2019				Planned	Milestone
Author Agreement		May 02, 2019 - May 06, 2019 (3)			May 6, 2019	Planned	Acknowledgem
Author Kick-Off Meeting		May 06, 2019				Planned	Event
Outline Review	Outline	May 08, 2019 - May 10, 2019 (3)			May 10, 2019	Planned	Review
1st Draft Review	1st Draft	May 15, 2019 - May 17, 2019 (3)			May 17, 2019	Planned	Review
1st Draft Review - 2nd Round	1st Draft	May 22, 2019 - May 24, 2019 (3)			May 24, 2019	Planned	Review
2nd Draft Review	2nd Draft	May 30, 2019 - Jun 03, 2019 (3)			Jun 3, 2019	Planned	Review
Approval for Submission		Jun 05, 2019 - Jun 07, 2019 (3)			Jun 7, 2019	Planned	Approval
Editorial Checklist - prior to Submission		Jun 11, 2019 - Jun 12, 2019 (2)			Jun 12, 2019	Planned	CheckList
Plain Language Summary		Jun 12, 2019				Planned	Milestone
Submission		Jun 13, 2019				Planned	Milestone
Decision		Jun 18, 2019				Planned	Milestone
Publication/Presentation		Jun 26, 2019				Planned	Milestone
Results Disclosure Date		Nov 13, 2019					Study

Add a PLS as a milestone in your output workflow

Other practical tools from Envision and our partners that can help you: PLS Toolkit (eg, PLS template, reviewer guides); Decision tree – which publications should have a PLS (avoid ‘cherry picking’ publications).

2

How have our PLS been accessed?

- # PLS accessed
- Access rates per PLS
- Time of access
- Method of access

Workflow State	Therapeutic Area	Product	Search Results
<input checked="" type="checkbox"/> Lorem ipsum dolor [25]	<input checked="" type="checkbox"/> Lorem ipsum dolor [25]	<input checked="" type="checkbox"/> Lorem ipsum dolor [25]	[1] Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim.
<input type="checkbox"/> Lorem ipsum dolor [5]	<input type="checkbox"/> Lorem ipsum dolor [5]	<input type="checkbox"/> Lorem ipsum dolor [5]	[2] Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim.
<input type="checkbox"/> Lorem ipsum dolor [1]	<input type="checkbox"/> Lorem ipsum dolor [1]	<input type="checkbox"/> Lorem ipsum dolor [1]	[3] Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim.
<input type="checkbox"/> Lorem ipsum dolor [0]	<input type="checkbox"/> Lorem ipsum dolor [0]	<input type="checkbox"/> Lorem ipsum dolor [0]	[4] Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim.
<input type="checkbox"/> Lorem ipsum dolor [0]	<input type="checkbox"/> Lorem ipsum dolor [0]	<input type="checkbox"/> Lorem ipsum dolor [0]	[5] Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim.

Store PLS in iLibrary

Metrics for plain language summaries (PLS)

Quick and easy ways Datavision can help you

POWERING
PATIENT VOICES

PLS metric

Datavision use

3

How many (# and %) of the authors' journal and congress targets accept PLS?

- Journals
- Congresses

<input type="checkbox"/>	Name	Publisher	ISSN	eISSN	Impact Factor	Acceptance Rate
<input checked="" type="checkbox"/>	High Blood Pressure & Cardiovascular Prevention	Adis, part of Springer Nature	1120-9879	1179-1985	0.000	33%
<input checked="" type="checkbox"/>	Pharmacoeconomics Open	Adis, part of Springer Nature	2509-4262	2509-4254	0.000	64%
<input checked="" type="checkbox"/>	Drugs	Adis, part of Springer Science+Business Media	0012-6667	1179-1950	4.690	56%
<input checked="" type="checkbox"/>	Drug Safety	Adis, part of Springer Science+Business Media	0114-5916	1179-1942	3.585	27%
<input checked="" type="checkbox"/>	Clinical Pharmacokinetics	Adis, part of Springer Science+Business Media	0312-5963	1179-1926	4.464	44%
<input checked="" type="checkbox"/>	Drugs & Aging	Adis, part of Springer Science+Business Media	1170-229X	1179-1969	2.381	34%
<input checked="" type="checkbox"/>	Pharmacoeconomics	Adis, part of Springer Science+Business Media	1170-7690	1179-2027	3.989	37%
<input checked="" type="checkbox"/>	Drugs & Therapy Perspectives	Adis, part of Springer Science+Business Media	1172-0360	1179-1977	0.000	92%
<input checked="" type="checkbox"/>	CNS Drugs	Adis, part of Springer Science+Business Media	1172-7047	1179-1934	4.206	39%
<input checked="" type="checkbox"/>	Clinical Drug Investigation	Adis, part of Springer Science+Business Media	1173-2563	1179-1918	1.918	35%
<input checked="" type="checkbox"/>	BioDrugs	Adis, part of Springer Science+Business Media	1173-8804	1179-190X	3.825	44%
<input checked="" type="checkbox"/>	Pediatric Drugs	Adis, part of Springer Science+Business Media	1174-5878	1179-2019	2.000	51%
<input checked="" type="checkbox"/>	American Journal of Clinical Dermatology	Adis, part of Springer Science+Business Media	1175-0561	1179-1888	3.018	24%
<input checked="" type="checkbox"/>	American Journal of Cardiovascular Drugs	Adis, part of Springer Science+Business Media	1175-3277	1179-187X	2.643	46%

Cross-check targets with PLS-accepting journals and congresses in the Journal and Congress database

4

How many patients are we partnering with and what is their role?

- PLS contributors
- Presentation contributors
- Publication contributors

Datavision (by Envision Pharma) - Training(Client Engagement)

File Edit View Tools My Notifications Archive Help

Workbench Chart View Profile Studies Journals Congress Library Documents Reports Contacts

Contacts Details Add Info Groups

* Last Name: Fisher * First Name: Alfie

* Organization: Envision Pharma Group Title: Dr

E-Mail: anna-lisa.fisher@envisionpharmagroup.com

Address: Work Phone: Fax: Alt number: Cell:

City: ZIP/Postal Code: Country:

Skills: Approver Author Editor Lead Investigator ☒ Patient Author Presenter

* Classification: External

Add patients' information (as permitted) and their role in Contacts

Other practical tools from Envision and our partners that can help you: Decision tree – which publications may be best suited for patient authorship (avoid 'token' contributions); Plain Language Guide of Good Publication Practice guidelines for patient contributors.

The Envision Pharma Group Plain Language Summaries of Publications Toolkit is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>). Attribution to Alligent Biopharm Consulting (Europe) Ltd.